Table 2.

Association between subclinical hypo- and hyperthyroidism and secondary outcomes

Secondary outcome/analysis	Subclinical hypothyroidism			Subclinical hyperthyroidism
	Euthyroid (E/N)	Shypo (E/N)	OR (95% CI)	Euthyroid (E/N)	Shyper (E/N)	OR (95% CI)
Pre-diabetes at last available follow-up	6539/22423	527/1782	0.94 (0.84–1.05)	6534/22365	229/825	1.03 (0.85–1.25)
Diabetes at first available follow-up	2097/36485	166/2931	1.02 (0.88–1.17)	1869/33240	64/1182	1.07 (0.82–1.40)
Pre-diabetes at first available follow-up	4358/22707	374/1774	0.96 (0.85–1.09)	4344/23085	143/864	1.03 (0.89–1.19)
Multivariable analysis*	2586/33552	223/2872	0.97 (0.82–1.13)	2313/31659	85/1088	1.00 (0.78–1.28)
Incident diabetes including aggregate data from Gronich et al22	−/87693	−/3064	1.12 (0.94–1.33)†	-	-	-
Time to diabetes (Cox regression)	3240/42562	283/3464	0.98 (0.87–1.11)‡	2959/38572	117/1267	1.07 (0.88–1.29)‡

E/N: Number of events/Total number of participants at follow-up; Shypo: subclinical hypothyroidism; Shyper: subclinical hyperthyroidism; OR: odds ratio; CI: confidence interval; HR: hazard ratio

^*Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, fasting blood sugar, smoking, total cholesterol, and body mass index. For the MrOS Study: data on diastolic blood pressure was not available. For the EPIC-Norfolk study, data on fasting blood sugar at baseline was not available, the model was adjusted for HbA1c at baseline. For the Busselton study: data on fasting blood sugar at baseline was not available, the model was adjusted for oral glucose tolerance test result at baseline

^†Incident diabetes analyzed as a risk ratio and data on number of events per category was not available for the study by Gronich et al.

^‡value is HR (95% CI)